Objective To investigate the clinical results and safety of cholinesterase inhibiting drugs on Alzheimer disease.Methods 72 cases of patients with Alzheimer disease were selected, which were treated in hospital from January 2015 to January 2016, and they were divided into the study group (36 cases) and control group (36 cases).The patients of control group were treated with quetiapine fumarate tablets ( an initial dose of 50 mg/d, bedtime;gradually increased to 100-400 mg/d) .On the basis of the control group, the patients of study group were treated with donepezil hydrochloride tablets ( an initial dose of 2.5-5 mg/d, orally at bedtime, increase to 10 mg /d after 1 week) .A course of two groups were all eight weeks.Compare the clinic results, adverse events, and changes of Mini Mental State Examination ( MMSE) , ADL Assess-ment Scale cognitive subscale ( ADAS cog) , activities of daily living scale ( ADL) and dementia pathology Behavior Scale (BEHAVE-AD), lipid peroxide (LPO ), superoxide dismutase (SOD) of two groups.Results The patients of the study group got a total efficiency of 94.4%, which was significantly better than the 77.8%of the control group (χ2 =4.181, P =0.041);The levels of MMSE score, SOD of the study group were significantly higher than those of the control group after the treatment ( t =5.269, t =1.753, t =4.797, t =4.380, t =2.459, t =1.723, P =0.000, P =0.041, P =0.000, P =0.000, P =0.000, P =0.044 );The levels of ADAS cog, ADL and BEHAVE-AD score, LPO of the study group were sig-nificantly less than those of the control group after the treatment ( t =4.797, t =4.380, t =2.459, t =1.723, P =0.000, P =0.000, P =0.000, P =0.044); There were drowsiness, nausea, paralysis, muscle tension, excitement, constipation and liver dysfunction and other symptoms occurred in patients of all two groups during treatment, but there was no significant difference between the two groups (χ2 =0.997,χ2 =0.997,χ2 =3.017,χ2 =2.060,χ2 =0.997,χ2 =0.504,χ2 =0.997, P =0.318, P =0.318, P =0.082, P =0.151, P =0.318, P =0.448, P =0.318 ).Conclusion With treating patients with Alzheimer disease, cholinesterase inhibiting drugs can obtain exact clinical efficacy, get fewer adverse reactions, and it is also safe, reliable, which makes it worthy of clinical application.%目的：观察胆碱酯酶抑制剂治疗老年认知功能障碍的临床效果和安全性。方法选取2015年1月—2016年1月陕西省安康市中心医院神经内科收治的老年认知功能障碍患者72例作为研究对象，按随机数字表法分为观察组36例和对照组36例。对照组给予富马喹硫平片，初始剂量50 mg／d，睡前服用，逐渐增至100～400 mg／d；观察组在对照组基础上联合应用盐酸多奈哌齐片，初始剂量2．5～5 mg／d，睡前口服，1周以后增加至10 mg／d。2组患者疗程均为8周。比较2组患者临床效果，分别于治疗前后采用简易精神状态量表（ MMSE）、AD评估量表认知分量表（ ADAS-cog）、日常生活功能量表（ ADL）及认知功能障碍病理行为评定量表（ BEHAVE-AD）对认知功能进行评定。抽血测定过氧脂质（ LPO）、超氧化物歧化酶（ SOD）水平，并记录2组患者不良反应。结果治疗后观察组总有效率为94．4％（34／36），显著高于对照组的77．8％（28／30），差异有统计学意义（χ2＝4．181， P ＝0．041）；与对照组比较，观察组MMSE评分、血清SOD水平明显提高，ADAS-cog、ADL、BEHAVE-AD评分及血清LPO水平显著降低，差异均有统计学意义（ t ＝5．269、1．753、4．797、4．380、2．459、1．723， P ＝0．000、0．041、0．000、0．000、0．000、0．044）；2组患者治疗过程中均出现嗜睡、恶心、神经麻痹、肌张力增高、兴奋、便秘及肝功能异常等症状，各种不良反应发生率比较差异无统计学意义（χ2＝0．997、0．997、3．017、2．060、0．997、0．504、0．997， P ＝0．318、0．318、0．082、0．151、0．318、0．448、0．318）。结论胆碱酯酶抑制剂治疗老年认知功能障碍患者疗效确切，不良反应小，安全可靠，值得临床推广应用。
展开▼
